key: cord-1049752-r7f2ib7f
authors: VanBlargan, Laura A.; Errico, John M.; Halfmann, Peter J.; Zost, Seth J.; Crowe, James E.; Purcell, Lisa A.; Kawaoka, Yoshihiro; Corti, Davide; Fremont, Daved H.; Diamond, Michael S.
title: An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodies
date: 2021-12-17
journal: bioRxiv
DOI: 10.1101/2021.12.15.472828
sha: d2fb0bd960a09b625f5a04316d41e6b58122c862
doc_id: 1049752
cord_uid: r7f2ib7f

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the global COVID-19 pandemic resulting in millions of deaths worldwide. Despite the development and deployment of highly effective antibody and vaccine countermeasures, rapidly-spreading SARS-CoV-2 variants with mutations at key antigenic sites in the spike protein jeopardize their efficacy. Indeed, the recent emergence of the highly-transmissible B.1.1.529 Omicron variant is especially concerning because of the number of mutations, deletions, and insertions in the spike protein. Here, using a panel of anti-receptor binding domain (RBD) monoclonal antibodies (mAbs) corresponding to those with emergency use authorization (EUA) or in advanced clinical development by Vir Biotechnology (S309, the parent mAbs of VIR-7381), AstraZeneca (COV2-2196 and COV2-2130, the parent mAbs of AZD8895 and AZD1061), Regeneron (REGN10933 and REGN10987), Lilly (LY-CoV555 and LY-CoV016), and Celltrion (CT-P59), we report the impact on neutralization of a prevailing, infectious B.1.1.529 Omicron isolate compared to a historical WA1/2020 D614G strain. Several highly neutralizing mAbs (LY-CoV555, LY-CoV016, REGN10933, REGN10987, and CT-P59) completely lost inhibitory activity against B.1.1.529 virus in both Vero-TMPRSS2 and Vero-hACE2-TMPRSS2 cells, whereas others were reduced (∼12-fold decrease, COV2-2196 and COV2-2130 combination) or minimally affected (S309). Our results suggest that several, but not all, of the antibody products in clinical use will lose efficacy against the B.1.1.529 Omicron variant and related strains.

with WA1/2020 D614G and B.1.1.529 in Vero-TMPRSS2 cells (Fig 2) . We with little inhibitory capacity even at the highest (10,000 ng/mL) concentration tested. COV2-107 2130 and COV2-2196 showed an intermediate ~12 to 150-fold (P < 0.0001) loss in inhibitory 108 activity, respectively against the B.1.1.529 strain. In comparison, S309 showed a less than 2-fold 109 (P > 0.5) reduction in neutralizing activity against B.1.1.529 (Fig 2a-h) . Analysis of mAb 110 combinations currently in clinical use showed that REGN10933/REGN10987 and LY-111

CoV555/LV-CoV016 lost all neutralizing activity against B.1.1.529, whereas COV2-112 2130/COV2-2196 showed a ~12-fold (P < 0.0001) reduction in inhibitory activity. 113

We repeated experiments in Vero-hACE2-TMPRSS2 cells to account for effects of 114 hACE2 expression, which can affect neutralization by some anti-SARS-CoV-2 mAbs 19 (Fig 3a-h) . In comparison, COV2-2196 showed moderately reduced activity (~16-fold) 121 as did the combination of COV2-2130/COV2-2196 mAbs (~11-fold). Unexpectedly, COV2-122 2130 did not show a difference in neutralization of WA1/2020 and B.1.1.529 in the Vero-123 hACE2-TMPRSS2 cells (Fig 3a, g, and h) , whereas it did in Vero-TMPRSS2 cells (Fig 2a, g,  124 and h). The S309 mAb showed less potent neutralizing activity in Vero-hACE2-TMPRSS2 cells 125 at baseline with a flatter dose response curve (Fig 3d) , as seen previously 6,24 , and showed a 126 moderate (~6-fold, P < 0.0001) reduction in neutralizing activity against B. substitution might negatively impact neutralization of some EUA mAbs given that it is a 169 crystallographic contact for COV2-2130, REGN10987, and S309 (Fig 1l) . At least for S309, the 170 R346K mutation did not impact neutralization of pseduoviruses displaying B. 

Pandemic 325 Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19

SARS-CoV-2 501Y.V2 escapes neutralization by South African 328 COVID-19 donor plasma

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating 330 variants

Neutralization of viruses with European, South African, and United States 332 SARS-CoV-2 variant spike proteins by convalescent sera and BNT162b2 mRNA 333 vaccine-elicited antibodies

Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7. 335

Resistance of SARS-CoV-2 variants to neutralization by monoclonal 337 and serum-derived polyclonal antibodies

In vivo monoclonal antibody efficacy against SARS-CoV-2 variant 339 strains

How bad is Omicron? What scientists know so far

Covid-19: Omicron may be more transmissible than other variants and partly 343 resistant to existing vaccines, scientists fear

Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis

B.1.1.529): Infectivity, vaccine 348 breakthrough, and antibody resistance

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-350 CoV antibody

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody 352 Sotrovimab

Potently neutralizing and protective human antibodies against SARS-354 CoV-2

REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in 356 rhesus macaques and hamsters

Complete map of SARS-CoV-2 358 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with 359 LY-CoV016

Effect of Bamlanivimab as Monotherapy or in Combination With 361

Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized 362 Clinical Trial

A therapeutic neutralizing antibody targeting receptor binding domain of 364 SARS-CoV-2 spike protein

A potently neutralizing SARS-CoV-2 antibody inhibits variants 366 of concern by utilizing unique binding residues in a highly conserved epitope

Neutralizing antibody and soluble ACE2 inhibition of a replication-369 competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2

The dual function monoclonal antibodies VIR-7831 and VIR-7832 372 demonstrate potent in vitro and in vivo activity against SARS-CoV-2. bioRxiv

Neutralizing and protective human monoclonal antibodies 375 recognizing the N-terminal domain of the SARS-CoV-2 spike protein

The Omicron Variant Increases the Interactions of 378 SARS-CoV-2 Spike Glycoprotein with ACE2. bioRxiv

Lectins enhance SARS-CoV-2 infection and influence neutralizing 380 antibodies

Predictions of the SARS-CoV-2 Omicron 382

Variant (B.1.1.529) Spike Protein Receptor-Binding Domain Structure and Neutralizing 383

Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine 385

medRxiv : the preprint server for health sciences

B.1.1.529 escapes the majority of SARS-CoV-2 neutralizing antibodies 388 of diverse epitopes. bioRxiv

Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron 390 antigenic shift. bioRxiv

Omicron likely to weaken COVID vaccine protection

SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer 393 BNT162b2 elicited neutralization and requires ACE2 for infection. medRxiv : the 394 preprint server for health sciences

Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 396 variant by post-immunisation serum. medRxiv : the preprint server for health sciences

Looking beyond COVID-19 vaccine phase 3 trials

Neutralizing antibody levels are highly predictive of immune 401 protection from symptomatic SARS-CoV-2 infection

Antibody potency, effector function, and combinations in protection 403 and therapy for SARS-CoV-2 infection in vivo

Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 405 Mortality

Human neutralizing antibodies against SARS-CoV-2 require intact 407

Fc effector functions for optimal therapeutic protection

r) New Perspective on SARS-CoV-2 Biology. 410 Cell

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the 412 ACE2 receptor

TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human 414 small intestinal enterocytes

Spike mutation D614G alters SARS-CoV-2 fitness

Syrian hamsters as a small animal model for SARS-CoV-2 infection and 417 countermeasure development

Rapid isolation and profiling of a diverse panel of human monoclonal 419 antibodies targeting the SARS-CoV-2 spike protein

Ultrapotent human antibodies protect against SARS-CoV-2 421 challenge via multiple mechanisms

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid 423 mutational escape seen with individual antibodies

LY-CoV555, a rapidly isolated potent neutralizing antibody, provides 425 protection in a non-human primate model of SARS-CoV-2 infection. bioRxiv (2020)

A human neutralizing antibody targets the receptor-binding site of SARS-427 CoV-2

Identification of SARS-CoV-2 spike mutations that attenuate monoclonal 429 and serum antibody neutralization

Inference of macromolecular assemblies from crystalline 431 state

Meeting modern challenges in visualization and 433 analysis